Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

4.5%

1 terminated out of 22 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

32%

7 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed with results

Key Signals

3 with results88% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (2)
P 1 (4)
P 2 (3)
P 3 (6)
P 4 (1)

Trial Status

Completed7
Recruiting5
Unknown5
Active Not Recruiting3
Terminated1
Withdrawn1

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT05044819Phase 4Active Not RecruitingPrimary

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

NCT05066217Phase 3RecruitingPrimary

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

NCT06464653Not ApplicableActive Not RecruitingPrimary

Pallidothalamic Tracts Electrical Stimulation for Lennox-Gastaut Syndrome

NCT05485831RecruitingPrimary

Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY

NCT05339126Phase 2Active Not Recruiting

RNS System LGS Feasibility Study

NCT03936777Phase 3Completed

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

NCT02307578Unknown

An Extended Access Program (EAP) for Perampanel

NCT06401538Phase 2Recruiting

BMB-101 in Absence Epilepsy and DEE

NCT05219617Phase 3Recruiting

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

NCT03778424UnknownPrimary

An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

NCT03355209Phase 3CompletedPrimary

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

NCT06149663Unknown

Intermediate-Size Expanded Access Protocol (EAP) for LP352

NCT05364021Phase 1Completed

Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

NCT05374824RecruitingPrimary

Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome

NCT04062981Phase 1CompletedPrimary

Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

NCT03467113Phase 1Completed

A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol

NCT02655198Phase 2Unknown

Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy

NCT03731715Phase 1CompletedPrimary

Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome

NCT03955432Not ApplicableTerminated

Long-term Cardiac Monitoring in Epilepsy

NCT02224560Phase 3Completed

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Scroll to load more

Research Network

Activity Timeline